Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Akeso, Inc. ( (HK:9926) ) is now available.
Akeso, Inc. announced that the U.S. FDA has approved its PD-1 monoclonal antibody, penpulimab-kcqx, for the treatment of advanced nasopharyngeal carcinoma (NPC) in two indications. This approval marks a significant milestone for Akeso, expanding the treatment options for NPC patients in the U.S. and highlighting the company’s commitment to addressing critical unmet medical needs. The approval is based on international clinical trials and follows previous designations by the FDA, underscoring the therapy’s potential impact on improving patient outcomes.
More about Akeso, Inc.
Akeso, Inc. operates in the biotechnology industry, focusing on the development of innovative immunotherapies. The company specializes in monoclonal antibodies, with a market focus on treating various cancers, including nasopharyngeal carcinoma and Hodgkin lymphoma.
YTD Price Performance: 53.05%
Average Trading Volume: 13,136,496
Technical Sentiment Signal: Sell
Current Market Cap: HK$79.35B
Learn more about 9926 stock on TipRanks’ Stock Analysis page.